Linagliptin

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. It works within the glucose‑regulation pathway to lower blood sugar levels.

• Type 2 diabetes mellitus: improves glycaemic control as monotherapy.
• Combination therapy with metformin: enhances overall glucose‑lowering effect.
• Adjunct to lifestyle modification: supports diet and exercise in achieving target HbA1c.

• Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones such as GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion and suppress glucagon release, resulting in reduced hepatic glucose production and improved post‑prandial glucose control.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nasopharyngitis: mild upper‑respiratory infection symptoms.
• Headache: transient mild to moderate pain.
• Upper respiratory tract infection: cough, sore throat.
• Dizziness: occasional light‑headedness.
• Nausea: mild gastrointestinal upset.
• Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain requiring immediate medical attention.
• Severe allergic reactions: anaphylaxis, angioedema, or skin rash.
• Hepatic injury: elevated liver enzymes or jaundice.
• Stevens‑Johnson syndrome: serious skin and mucosal involvement.
• Hypoglycaemia (when combined with insulin or sulfonylureas): symptomatic low blood glucose.
• Bullous pemphigoid: rare autoimmune blistering skin disease.

Before initiating linagliptin, clinicians should consider several safety aspects.

• Renal impairment: monitor renal function; dose adjustment usually not required but caution advised.
• Hepatic impairment: use with caution and monitor liver enzymes.
• Risk of hypoglycaemia: heightened when combined with insulin or sulfonylureas.
• Pancreatitis: advise patients to report persistent abdominal pain.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Concomitant use with insulin or sulfonylureas: increased risk of hypoglycaemia.
• Strong P‑glycoprotein inhibitors (e.g., itraconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely)

• Rifampin or other enzyme inducers: may reduce linagliptin exposure.
• Diuretics: potential for dehydration, monitor renal function.
• ACE inhibitors or ARBs: observe for additive blood pressure effects.